Anand Vijayakumar Palur Ramakrishnan

Dr. Anand Vijayakumar Palur Ramakrishnan


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2016 in Cardiovascular Therapeutics
Verified
Journal Article
Closed access
PDF file
ARAnand Vijayakumar Palur Ramakrishnan
Anand Vijayakumar Palur Ramakrishnan
ARAnand Vijayakumar Palur Ramakrishnan
Anand Vijayakumar Palur Ramakrishnan
TVTreesa P. Varghese
Treesa P. Varghese
SVSreedevi Vanapalli
Sreedevi Vanapalli
NNNarayanan K. Nair
Narayanan K. Nair
MMMenge Denis Mingate
Menge Denis Mingate

16 December 2011 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
APArun K. P.
Arun K. P.
VMVenkata Subbaiah Meda
Venkata Subbaiah Meda
VKV. S. P. Raj Kucherlapati
V. S. P. Raj Kucherlapati
ADAnil Dubala
Anil Dubala
DMDeepalakshmi M.
Deepalakshmi M.
SBSuresh B.
Suresh B.

19 May 2020 in Current Cardiology Reviews
Verified
Journal Article
Open access
PDF file
TVTreesa P. Varghese
Treesa P. Varghese
ARAnand Vijayakumar Palur Ramakrishnan
Anand Vijayakumar Palur Ramakrishnan
NVNila Mary Varghese
Nila Mary Varghese
SCSharad Chand
Sharad Chand
Depressive symptoms are highly prevalent in patients with cardiac diseases. Co-morbid Depression in cardiac patients causes a significant reduction in health-related quality of life for the patients and inflicts an economic burden on the society. Two types of mechanisms that may explain the link between depression and cardiac diseases are the psychosocial and physiopathological mechanisms. Physiopathological mechanisms are direct biological mechanisms, which include hyperactivity of non-adrenergic and Hypothalamic Pituitary Adrenal Axis (HPA), abnormal platelet activation, endothelial dysfunction, and inflammatory process. Psychosocial factors include behavioral or lifestyle factors like smoking alcoholism and physical inactivity. Pharmacologic and therapeutic interventions are effective at reducing symptoms of depression in patients with cardiac disorders. Among pharmacological treatment, SSRIs seems to be effective for the reduction of depressive symptoms among patients with cardiac disorders because of their good efficacy and minimal cardiovascular side effects. Mechanisms of action of SSRI’s in depressive patients with cardiac disorders are associated with their ability to reduce inflammation, platelet, and endothelial dysfunction. This review focuses on the potential pathophysiological and psychosocial links between cardiac diseases and depression, the treatment options, and the importance of routine screening of depressive symptoms in cardiac settings.

1 May 2007
Verified
Journal Article
Closed access
MRM Ramanathan
M Ramanathan
SSS Sivakumar
S Sivakumar
ARAnand Vijayakumar Palur Ramakrishnan
Anand Vijayakumar Palur Ramakrishnan
CSC Saravanababu
C Saravanababu
PPP Rathinavel Pandian
P Rathinavel Pandian

27 March 2026 in Journal of Radioanalytical and Nuclear Chemistry
Verified
Journal Article
Closed access
PDF file
TVTreesa P. Varghese
Treesa P. Varghese
AVAnjaly Vijayan
Anjaly Vijayan
NMNazija Mpc
Nazija Mpc
MAMaryam
Maryam
ARAnand Vijayakumar Palur Ramakrishnan
Anand Vijayakumar Palur Ramakrishnan

6 March 2026 in Current Diabetes Reviews
Verified
Journal Article
Open access
PDF file
PGPrashant Ghimiray
Prashant Ghimiray
ARAnand Vijayakumar Palur Ramakrishnan
Anand Vijayakumar Palur Ramakrishnan
GMG.R. Meghna
G.R. Meghna
RJRimsha Jamil
Rimsha Jamil
This narrative review aims to elucidate the significance of the synergistic effects of linagliptin and resveratrol and also explores their individual mechanisms of action in diabetic complications such as nephropathy. A systematic literature analysis examined the synergistic potential of resveratrol and linagliptin in diabetic nephropathy. A critical review of their antioxidant, anti-inflammatory, and anti-fibrotic mechanisms was conducted. Various studies revealed that linagliptin improves renal outcomes through both incretin-dependent and independent pathways, reducing oxidative stress, inflammation, and AGE-RAGE axis activation. It also exhibits the capacity to reduce albuminuria and renal fibrosis in diabetic animal models. Resveratrol similarly demonstrates substantial renoprotective benefits through activation of the AMPK/Nrf2 pathway, mitigating oxidative stress and downregulating inflammatory markers such as tumor necrosis factor-alpha and interleukin-1 beta. The synergistic use of linagliptin and resveratrol may provide greater benefits than their individual effects, including improved glycaemic control, reduced renal oxidative stress, and decreased inflammatory and fibrotic markers, thereby offering superior protection against diabetic nephropathy.